Cytokinetics

Historical price data

Cytokinetics' mission is to develop innovative medicines that improve the healthspan of patients suffering from cardiovascular and neuromuscular diseases characterized by compromised muscle function. Its key achievement is the 2025 FDA approval of MYQORZO (aficamten), a first-in-class cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy (oHCM), validating its decades-long focus on sarcomere biology. The company's strategy is to build a leading muscle-focused specialty biopharma business by commercializing aficamten across HCM subtypes, advancing late-stage candidates in heart failure, and leveraging its platform to develop treatments for neuromuscular conditions like ALS.

Proprietary platform focused on sarcomere biology, enabling the discovery and development of small molecule muscle inhibitors (e.g., cardiac myosin inhibitors) and activators (e.g., cardiac myosin and troponin activators) to treat diseases of impaired muscle function.